



## PATENT APPLICATION

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventor(s) Patrizio Mattei, et. al.

Group:

Serial No. 10/613,782, filed July 3, 2003

Examiner:

Docket No. 21159

For: QUINAZOLINE DERIVATIVES

## **INFORMATION DISCLOSURE STATEMENT**

Nutley, New Jersey 07110 September 26, 2003

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

Documents A1-A7, and B1-B11 listed on Form PTO-1449 are enclosed.

Documents B4, B5 and B6, which are not written in the English language, correspond to Documents A3, A4, and A5, respectively.

Consideration of all the documents cited on Form PTO-1449 is requested.

Serial No. 10/613,782

Filed: July 3, 2003

Since the Information Disclosure Statement is submitted before the mailing of the first Office Action on the merits or within three months of the filing date for the above application, no fee is due.

Respectfully Submitted,

Attorney for Applicant

Eileen M. Ebel (Reg. No. 37,316)

340 Kingsland Street

Nutley, New Jersey 07110 Telephone: (973) 235-4391

Telefax: (973) 235-4391

134562

PTO/SB/21 (01-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE are required to respond to a collection of information unless it displays a valid OMB control number. **Application Number** 10/613.782 TRANSMITTAL Filing Date July 3, 2003 **FORM** First Named Inventor Mattei Art Unit (to be used for all correspondence after initial filing) **Examiner Name** Attorney Docket Number 21159 Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to Group Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers of Appeals and Interferences Fee Attached Appeal Communication to Group Petition (Appeal Notice, Brief, Reply Brief) Amendment/Reply Petition to Convert to a **Proprietary Information** After Final Provisional Application Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Terminal Disclaimer Identify below): Extension of Time Request Request for Refund **Express Abandonment Request** CD, Number of CD(s) Information Disclosure Statement Remarks Certified Copy of Priority Document(s) Form 1449 with references Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Eileen M. Ebel

CERTIFICATE OF TRANSMISSION/MAILING									
I hereby certify that this co mail in an envelope addres	rrespondence is being tra ssed to: Commissioner for	nsmitted to the USPTO or deposited with the Ur Patents, P.O. Box 1450, Alexandria, VA 2231	nited States Postal Service with sufficient postage as first class 13 on this date September 26, 2003						
Typed or printed	Eileen M. Ebel								
Signature	Lilu	m El	Date September 26, 2003						

Individual Signature Date

September 26, 2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.** 

1 Th		Substitute f	for form 1449A/PTO	- Τ	Complete if Known				
EINE	INFORMATION DISCLOSURE				Application Number	10/613			
	STATEMENT BY APPLICANT						2003		
				<u> </u>	First Name Inventor	Mattei	<del></del>		
<b>y</b>	(Use sev	eral shee	ets if necessary)	Ī	Group Art Unit				
			Examiner Name						
Sheet 1		of	1		Attorney Docket Number	21159			
•					ENT DOCUMENTS	*****	· • · · · · · · · · · · · · · · · · · ·		
	<u> </u>	U.S. Patent Document  Kind Code²  Number (if known)			Name of Patentee or Applicant of Cited Document		Date of Publication		
Examiner Cite Initials' No.'							Cited document MM-DD-YYYY		
	A1	4,59	8,089		Hadvary, et. al.		07/01/1986		
	A2	6,00	4,996		Shah, et. al.		12/21/1999		
	A3 4,931,463 A4 4,983,746			Barbier, et. al. Barbier, et. al.		06/05/1990 01/08/1991			
	A5	5,399,720		Karpf, et. al.	· · · · · · · · · · · · · · · · · · ·		03/21/1995		
	A6	4,035,367		Simpson, William R			07/12/1977		
	A7	6,573,263		Niewohner, et. al.			06/2003		
	12.				, , , , , , , , , , , , , , , , , , , ,				
	L	L	FO	REIGN P.	ATENT DOCUMENTS				
Fo		Forei	Foreign Patent Document			Da	Date of Publication of Cited Document MM-DD-YYYY		
Examiner	Cite No. <sup>1</sup>	Office	Office <sup>3</sup> Number Kind						
Initials'		(if known)		(if known)	<del></del>		7/15/1999		
	B1	WO 99/34786					113/1999		
	DO	WO 00/09122			Pharmaceuticals, Inc. F. Hoffmann-La Roche AG		02/24/2000		
	B2								
	Da	WO 00/09123			F. Hoffmann-La 02 Roche AG		2/24/2000	-	
	B3						2/24/2000		
							06/25/1986		
	B4	EP 0 185 359		110111111111111111111111111111111111111		0/25/1980			
	D.7				& Co.		08/06/1986		
	B5	EP 0 189 577		Hoffmann-La Roch					
	D.C	ED.	0.440.440		Ltd.	0 00	3/28/1991	+	
	B6	EP 0 443 449					0/20/1991		
	D.Z.	ED 0 524 405			& Co.		01/27/1002		
	B7	EP 0 524 495				1/27/1993			
	Do	W/O 02 20 /00			Roche & Co.		2/14/2002		
	B8	WO 02 20488				3/14/2002			
<del></del>	Do				Roche AG		1/29/2002	+	
	B9	l wo	02 094789		F. Hoffmann-La		1/28/2002		
	<u> </u>	\	066=4=1		Roche AG		1/20/1007	+	
:	B10	WO	96 37474		Warner-Lambert	1.	1/28/1996		
	<u> </u>	ļ			Company		4/05/0001	1	

	D . O . I .	
Examiner	Date Considered	
Signature		}

Neurogen Corporation

04/05/2001

WO 01 23389

B11

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*Unique citation designation number: \*See attached Kinds of U.S. Patent Documents. \*Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language Translation or abstract is attached.